Grifols Stock News

This REIT has it all.

Another player has stuffed its pipeline with many coronavirus candidates.

Grifols (GRFS) unit Araclon Biotech reported results for the first part of its phase 2 trial of its vaccine ABvac40 for Alzheimer''s Disease ((AD)) and data on two studies of its…

BARCELONA, Spain, March 2, 2022 /PRNewswire/ -- Grifols , a global leader in plasma-derived medicines with more than 110 years of history helping to improve the health and well-being of people,… | March 2, 2022

BARCELONA, Spain, March 2, 2022 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), a global leader in plasma-derived medicines with more than 110 years of history helping to improve the health and well-being of people, today announced it is partnering with Feeding America, the…

Grifols Earnings, Revenue Miss in Q4

BARCELONA (Reuters) – Spanish pharmaceutical company Grifols said on Monday its 2021 net profit fell 70% to 183 million euros ($204.70 million) as the COVID-19 pandemic continued to disrupt supplies of the blood plasma it uses to make medicines.

Grifols (GIKLY) is collaborating with Endpoint Health to develop and commercialize an Antithrombin III (AT-III) therapy to treat Sepsis.Under the agreement, Grifols will contribute…

BARCELONA, Spain, Feb. 24, 2022 /PRNewswire/ -- Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), one of the world''s leading producers of plasma-derived medicines, today announced a collaboration with Endpoint Health, Inc., a precision-medicine therapeutics company dedicated to addressing…

PALO ALTO, Calif.--(BUSINESS WIRE)--Endpoint Health, Inc., a precision-firstTM therapeutics company dedicated to addressing urgent needs in immune-driven critical and chronic illnesses, today announced that the company has entered into a global collaboration and licensing agreement with Grifols, a leading global producer of plasma-derived medicines, under which Endpoint Health will receive exclusive rights to develop and commercialize Antithrombin III (AT-III) in sepsis. Under the terms of the

Grifols S.A. (NASDAQ:GRFS) shares, rose in value on Friday, 02/18/22, with the stock price up by 1.36% to the previous days close as strong demand from buyers drove the stock to $11.20. Actively observing the price movement in the last trading, the stock closed the session at $11.05, falling within a range of $11.01 and Grifols S.A. (NASDAQ: GRFS): Aiming For A Higher Share Price Read More »

Grifols currently trades at a 30% discount to European specialty pharma. GIFLF has a successful track record of M&A and is currently trading on a 2022 P/E of 16.5.

Grifols: Short-Term Turbulence But Long-Term Upside

Their dividends will be trickling into your account quarter after quarter.